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Abstract
The lipocalin apolipoprotein D (Apo D) is upregulated in peripheral nerves following injury and in regions of the
central nervous system, such as the cerebral cortex, hippocampus, and cerebellum, during aging and progression of
certain neurological diseases. In contrast, few studies have examined Apo D expression in the brainstem, a region
necessary for survival and generally less prone to age-related degeneration. We measured Apo D expression in
whole human brainstem lysates by slot-blot and at higher spatial resolution by quantitative immunohistochemistry in
eleven brainstem nuclei (the 4 nuclei of the vestibular nuclear complex, inferior olive, hypoglossal nucleus,
oculomotor nucleus, facial motor nucleus, nucleus of the solitary tract, dorsal motor nucleus of the vagus nerve, and
Roller`s nucleus). In contrast to cortex, hippocampus, and cerebellum, apolipoprotein D was highly expressed in
brainstem tissue from subjects (N = 26, 32−96 years of age) with no history of neurological disease, and expression
showed little variation with age. Expression was significantly stronger in somatomotor nuclei (hypoglossal,
oculomotor, facial) than visceromotor or sensory nuclei. Both neurons and glia expressed Apo D, particularly neurons
with larger somata and glia in the periphery of these brainstem centers. Immunostaining was strongest in the
neuronal perinuclear region and absent in the nucleus. We propose that strong brainstem expression of Apo D
throughout adult life contributes to resistance against neurodegenerative disease and age-related degeneration,
possibly by preventing oxidative stress and ensuing lipid peroxidation.
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Introduction
Apolipoprotein D is a glycoprotein first isolated from the
plasma HDL fraction and also found in smaller amounts in
VLDL and LDL. The amino acid sequence shows a high
homology with the lipocalin family but not with other
apolipoproteins. The main role of Apo D is still uncertain, but by
analogy with other lipocalins it may serve as a transporter of
small hydrophobic molecules between the circulation and
tissue [1]. The gene for human Apo D (at 3p14.2) was cloned
and sequenced in 1986, and mRNA expression subsequently
demonstrated in many tissues [2].
The Apo D protein has since been detected in many organs,
tissues, and body fluids of both humans and other species [3],
and is probably able to interact with a variety of different
ligands depending location and physiological requirements.
Adrenal gland and kidney express the highest levels of Apo D
mRNA, and expression is also intense in pancreas, placenta,
spleen, lung, ovary, testis, brain, and peripheral nerves.
Lachrymal secretions, axillary apocrine gland secretions, urine,
cerebrospinal fluid (CSF), and perilymph and middle ear fluid
also contain Apo D [3]. At the cellular level, Apo D is commonly
expressed by fibroblasts, especially those close to vessels [4].
In the human peripheral nervous system (PNS), Apo D is
synthesized and secreted by fibroblasts and Schwann cells
under basal conditions and upregulated during regenerative
processes that follow injury. Following sciatic nerve injury, Apo
D mRNA and protein expression levels increase to levels much
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higher than all other apolipoproteins [5,6]. Like Apo E, Apo D is
synthesized locally, while Apo AI and Apo A-IV are derived
from the bloodstream [5]. Peripheral nerve injury is
accompanied by the release of hydrophilic molecules initially
deposited in Schwann cells, macrophages, and neurilemmal
cells. Cholesterol, together with other lipids, is then used for
restructuring and membrane biogenesis. Apolipoproteins
contribute to the mobilization of lipids and cholesterol
homeostasis and have complementary roles in nerve injury in
the absence of other apolipoproteins [7].
The human central nervous system (CNS) expresses a
unique Apo D isoform with lower molecular weight (29 kD) than
that founded in CSF or plasma (32 kD). In humans and other
mammals, immunohistochemical and hybridohistochemical
techniques have demonstrated Apo D on the surfaces of glial
cells (astrocytes, oligodendrocytes, and microglia), pial cells,
perivascular cells, and neurons [4,8–13].
Apolipoprotein D expression is more intense in white matter
than grey matter due to particularly strong expression in
oligodendrocytes, where it may be involved in myelination [7].
On the contrary, expression is lower in neurons and astrocytes
and more variable across brain regions [8,9]. Furthermore, the
synthesis of Apo D by astrocytes is elevated by activation in
response to injury, termed reactive astrogliosis [10]. The fact
that Apo D localizes to ependimocytes, glial cells, neuropil, and
perivascular cells suggests that it could be a bidirectional
carrier of small molecules through the blood-brain barrier (BBB)
and (or) blood-CSF barrier (BCB) [8,9,14].
Increased expression of Apo D in the CNS has been
observed in neurodegenerative and neuropsychiatric disorders
(for review see 15,16). In some of these diseases, such as
Alzheimer's disease (AD) and multiple sclerosis (MS), elevated
Apo D expression has also been observed in the cerebrospinal
fluid and plasma [17,18]. Furthermore, the correlation between
regional Apo D expression pattern and sensitivity to neural
pathology associated with these disorders suggests that Apo D
is a marker for brain structures prone to neuropathology, such
as the frontal cortex, entorhinal cortex, and hippocampus in
AD, pre-frontal cortex in schizophrenia, and temporal cortex in
bipolar disorder [17,19,20]. There has been little work on Apo D
expression in mid- or hindbrain structures such as the pons
and medulla, regions with distinct anatomical structures and
rudimentary functions essential for life.
In this study, we examined the expression of Apo D in
brainstem extracts by slot-blot and in fixed sections by
immunohistochemistry. Tissues were obtain from subjects of a
broad range of ages to examine age-related expression
changes in both whole brainstem and 11 well defined nuclei of
the human medulla oblongata and pons.
Materials and Methods
1. Human tissues
Use of human brain tissues were approved by “Comité Ético
de investigación Clínica Regional del Principado de Asturias”
as follows. These studies were granted waivers of consent on
the following bases: 1) samples were gathered retrospectively
from pathology archives of necropsies performed for diagnostic
purposes; 2) patient identities were anonymized and
completely delinked from unique identifiers; and 3) there was
no risk to the participants.
All human brain tissue samples were provided by the
Department of Pathologic Anatomy of the Central Hospital of
Asturias and obtained from necropsies within 6 h of death.
These samples were the same as those used in previous
studies by our group [8-10,21]. Twenty-six brainstems from
men 32−92 years old were examined. None of the patients
presented a previous inner ear or neurological disease. In all
cases, macroscopic and microscopic examination revealed the
absence of acute, chronic, localized, or diffuse brain pathology.
Tissue blocks were cut into 1 cm slices perpendicular to the
brainstem axis. Two samples were obtained from each case;
one was frozen at -80 ° C for protein extraction and the other
fixed in paraformaldehyde (in 0.1 M phosphate buffer, pH 7.4)
for neuropathological diagnosis and immunohistochemical
studies. Due to the structure of the nuclei studied, samples for
slot blots were not separated into white and grey matter
sections. The present study was conducted according to the
Declaration of Helsinki and was approved by the “Comité Ético
de investigación Clínica Regional del Principado de Asturias”
(Spain).
2. Protein slot-blotting
Apo D levels were quantified using a slot blot technique [9].
Samples from human breast cyst fluid were also included as a
positive control for Apo D detection, and ExtrAvidin-Alkaline
Phosphatase (Sigma, E26366) was used as an internal control.
Briefly, 0.06, 0.12, 0.25, 0.5, 1.0, and 2.0 μg samples of total
protein were slot blotted under vacuum in a Bio Dot apparatus
(Biorad). Nitrocellulose membranes were then immunostained
for Apo D protein according to the following protocol. Non-
specific binding was blocked by incubation of membranes with
1% bovine serum albumin (BSA). Blocked membranes were
then incubated for 1 hour at room temperature with a primary
antibody against human Apo D (1:10,000; a gift from Dr. Carlos
López Otín, Departamento de Bioquímica y Biología Molecular,
Universidad de Oviedo) [8,22-24]. After 3 washes of 15 min
each in PBS, membranes were incubated for 30 min at room
temperature in biotinylated monoclonal anti-rabbit IgG
(1:10,000; Sigma, B 5283), washed again as before, and then
incubated with ExtrAvidin Alkaline Phosphatase (1:10,000;
Sigma, E26366). After three washes of 15 min each in PBS,
enzyme activity was measured by incubation in Sigma Fast
BCIP/NBT solution (Sigma, B5655) for 2 hours at room
temperature.
The blots of Apo D were dried and bands quantified as
relative optical densities (arbitrary units) using a digital scanner
(Nikon AX-110, Nikon) and ImageJ 1.37c (National Institutes of
Health, Bethesda, MD, USA) [9].
3. Cytoarchitectonic staining and
Immunohistochemistry
After fixation, tissue blocks were washed in distilled water,
dehydrated, cleared in butyl acetate, and embedded in paraffin.
Sections were cut at 10 μm thickness and mounted on
"SuperFrost Plus" (Mentzel-Glasse) slides, dried at 36 °C for
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24 h, deparaffined in xylene, and partially rehydrated by
incubation in a graded alcohol series (2 min per concentration).
In each case, every 80th or 160th section was stained by the
Nissl/Myelin technique [25] and examined for
myelocytoarchitecture. The brainstem nuclei examined were
the principal inferior olivary nucleus (IO), the hypoglossal
nucleus (XII), the oculomotor nucleus (III), the facial nucleus
(VII), the Roller nucleus (RN), the dorsal motor nucleus of the
vagus nerve (DX), nucleus of the solitary tract (NST), inferior
vestibular nucleus (IVN), medial vestibular nucleus (MVN),
lateral vestibular nucleus (LVN), and superior vestibular
nucleus (SVN). The boundaries of these nuclei were defined
according to [26] as in previous studies by our group [27,28].
For immunohistochemistry, fixed sections were permeablized
with triton X (0.1%, 5 min), washed in distilled water, treated
with H2O2 (3%, 5 min) to quench endogenous peroxidase
activity, washed in distilled water, and treated with PBS. After
blocking non-specific binding by incubation in BSA (30 min),
sections were incubated with the antibody against human Apo
D (1:2,000) overnight at 4 °C. Immunoreactivity was detected
using the Extravidin biotin peroxidase staining kit (Sigma Extra
3), and peroxidase activity visualized by incubation with Sigma
Fast DAB (Sigma D4168) at room temperature for 30 min.
Finally, the sections were counterstained using a modified
formaldehyde thionin method [29], dehydrated, cleared in
eucalyptol, and mounted with Eukitt. For controls,
representative sections were processed in the same way with a
non-immune serum or specifically absorbed sera in place of the
primary antibody. Under these conditions, no specific
immunostaining was observed.
4. Quantification of Apo D Expression
For quantification of Apo D expression, the chromogenic
signal was selected using Adobe Photoshop CS 8.0.1 (Adobe
Systems Inc., CA, USA) and density measured by ImageJ
1.37c (National Institutes of Health, Bethesda, MD, USA)
according to a procedure developed by our group [30]. Briefly,
sections were photographed with a digital camera and the
images imported into Adobe Photoshop. For subsequent
comparison of Apo D expression in different sections, the
magnification of images must also be equal. The analysis
protocol is as follows: (1) To select the specific chromogenic
signal, choose “Color range” in the “Select menu” of
Photoshop, and with the “Eyedropper” tool click on any object
in the image displaying the desired color/chromogen and all
areas within the selected color range will be highlighted in an
automatically generated clone image. The tolerance bar of the
color range tool makes direct visualization of the selected
regions possible with minimal variations in the chromogen
selection. Once chromogen selection is finished, the profile
used can be archived for use with similar stained sections (2).
Close the “Color range” panel and all immunopositive objects in
the original image appear highlighted (3). Open the “Edit” menu
of Photoshop, select “Copy”, open a “New file”, and “Paste” the
selected image. The new image shows only the positive
selected areas on a white background (4). Convert the image
to greyscale so all selected marked areas are represented in
grey tones correlated with chromogen intensity. This greyscale
picture must be saved in ‘tif’ format, which can then be opened
in Scion Image (or other free image analysis programs such as
ImageJ) (5). Open the picture in this program and calculate the
“Mean density” under “Uncalibrated” conditions. The
measurements obtained show the signal strength and can be
copied and exported to a spreadsheet (i.e., Excel). The signal
strength varies between 0 and 255 (value 0 corresponds to a
nonstained section (white), and 255 corresponds to a fully
stained section (black).
5. Statistical analyses
All statistical calculations were conducted using SPSS 15.0
for Windows. Data sets were first tested for normality using the
Kolmogorov-Smirnov test with Lilliefors correction. Expression
levels of Apo D were compared among nuclei by the Mann-
Whitney U test due to non-homogeneity of variance. A P value
< 0.05 was considered statistically significant.
Results
1. Apo D protein levels
The levels of Apo D expression were measured in 26 human
brainstem samples from patients ranging in age from 32 to 96
years. Densitometric analysis of slot blots showed robust and
relatively stable expression throughout adult life, particularly
between the forth and eighth decades (Figure 1). Regression
analysis showed no statistically significant increase in
expression with age.
2. Tissue distribution of Apo D protein
Expression of Apo D was also measured at the cellular level
in 11 pontine and medullar nuclei of both sensorial and motor
functional systems (Figure 2). All special somatosensory nuclei
studied are components of the vestibular nuclear complex
(VNC). In addition, we assessed Apo D expression in the
inferior olivary nucleus (IO), which does not belong to either the
general or special somatosensory system but has
somatosensory functions (Figure 2). We also studied the
hypoglossal nucleus (XII), oculomotor nucleus (III) and the
facial motor nucleus (VII) as examples of somatomotor and
branchimotor nuclei. The nucleus of the solitary tract (NST) and
the dorsal motor nucleus of the vagus nerve (DX) were studied
as examples of visceromotor nuclei. Finally, we studied a small
motor nucleus located in the middle reticular substance named
Roller`s nucleus (RN).
2.1. Somatomotor and branchimotor system nuclei.  All
somatomotor and branchimotor system nuclei studied showed
robust Apo D immunoreactivity throughout life. The hypoglossal
nucleus (XII), located in the middle and lower third of the
medulla oblongata, is part of the somatic motor column of the
brainstem. This somatomotor nucleus (Figure 3A, B) exhibited
the highest level of Apo D staining after the facial nucleus
(Figure 3E, F). In XII, protein expression was not evenly
distributed but rather located principally in larger neurons
(Figure 3B). There was no significant relationship between Apo
D expression and age, but there was a modest tendency for
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total protein expression to diminish in older subjects (r =
-0.5239; p > 0.05).
The oculomotor or abducens nucleus (III) is also part of the
somatic motor column of the brainstem and shares many
characteristics with XII (Figure 3C, D). The III also exhibited
intense Apo D immunoreactivity, but expression was
heterogeneous, with the middle third showing the greatest
protein expression, coinciding with the highest cell density.
Figure 1.  Slot blot analysis and amount of Apo D protein along different ages and decades.  A) Samples from medulla
oblongata of different subjects during aging. B) Amount of Apo D in samples from subjects between 35 and 82 years old. The
graphic shows the densitometric analysis of slot blots. Data presented as means of relative optical density (ROD). Each point in the
graph represents mean density ±standar error of the mean. Regresion lines and Pearson`s correlation coefficient (r) is also shown.
doi: 10.1371/journal.pone.0077852.g001
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Figure 2.  Hemisections of medulla oblongata.  Four levels of medulla oblongata (A,B,C,D), stained with a Nissl/Myelin
technique, with the localization of the different nuclei studied in the present paper are showed.
doi: 10.1371/journal.pone.0077852.g002
Apo D Expression in Human Brainstem
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Figure 3.  Immunohistochemistry for Apo D and amount of Apo D protein in some nuclei along different decades.  A, B)
Hypoglossal nucleus (XII). C,D) Oculomotor nucleus (III). E, F) Facial motor nucleus (VII). Roller`s nucleus (RN). Data presented as
means of relative optical density (ROD). Each point in the graph represents mean density in a x20 field ±standar error of the mean.
Regresion lines and Pearson`s correlation coefficient (r) are also shown. Bar: 40 μm.
doi: 10.1371/journal.pone.0077852.g003
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There was no significant relationship between Apo D
expression and age, but there was a slight tendency for total
protein expression to increase (r = 0.2098; p > 0.05). As in the
other nuclei studied, Apo D was present in almost all neurons
of medium and large size.
The facial nucleus (VII), a nucleus with well described
topographic organization, contained many large Apo D-positive
neurons and showed the highest Apo D expression of all nuclei
studied (Figure 3E, F). The density of stained cells was highest
in the middle third of the nucleus, decreasing in the rostral and
caudal ends. There was no change in Apo D expression with
age (r = -0.0329; p > 0.05; Figure 3E).
The immunoreactivity of Roller’s nucleus (Figure 3G, H) was
also very high despite being smaller than the other nuclei
studied (Figure 3G, H). We found no significant relationship
between age and total Apo D expression in RN, but there was
a slight tendency to increase with age (r = 0.5404; p > 0.05).
2.2. Viscerosensory and visceromotor system
nuclei.  The DX (Figure 4A, B) and NST (Figure 4C, D) were
studied as examples of visceromotor nuclei. Both exhibited low
intensity immunostaining compared to the somatomotor and
branchiomotor nuclei, and showed no statistically significant
changes with age (r = 0.0059; r = 0.2981; p > 0.05). In general,
these low levels of Apo D expression mirrored other sensory
nuclei (Figure 5), with all showing lower immunoreactivity than
somatomotor nuclei (Figure 6).
2.3. The inferior olive and somatosensory system
nuclei.  The general and special somatosensory nuclei of the
brainstem are located in the pons and medulla oblongata. We
also studied IO (Figure 4E, F) due to its somatosensory
functions and because the cytoarchitectural features can be
easily delimited. The mean densitometric value of Apo D
expression in the IO was intermediate between the motor
nuclei (with generally high expression) and the sensory nuclei
(with generally low expression). There was no statistically
significant relationship between the densitometric value of Apo
D staining and age, but there was a small tendency for
increased expression with age (r = 0. 1377; p > 0.05).
The VNC consists of inferior (IVN), lateral (LVN), medial
(MVN), and superior (SVN) components. The IVN contains
neurons of a broad range of sizes, but medium-size neurons
are predominant (Figure 5A, B). The IVN and LVN had the
highest levels of Apo D expression in the VNC. In the IVN, Apo
D expression was located only in the cytoplasm of larger
neurons. No statistically significant relationship between age
and Apo D expression was found in the IVN, although there
was a modest trend for a decrease with age (r = -0.414; p >
0.05). The MVN is the largest nuclei of the VNC and densely
packed with intermediate-size neurons. Despite the high cell
density, Apo D expression was relatively low. Staining was
preferentially located in neurons of greatest size (Figure 5C,
D). Densitometric analysis revealed no significant changes in
expression with age (r = 0.0033; p > 0.05). The LVN exhibited
the highest Apo D expression in the VNC but again with no
significant age-related changes (r = -0.2228; p > 0.05). In the
LVN, all giant neurons (Deiters’ cells) showed high levels of
Apo D expression regardless of subject age (Figure 5E, F). The
SVN consists of large neurons arranged in nests among
myelinated fibres that cross the nucleus as well as smaller
isolated neurons (Figure 5G, H). The SVN expressed the least
amount of Apo D of all VNC components and also showed no
statistically significant changed in expression with age (r =
-0.2458; p > 0.05).
Unlike forebrain regions and cerebellum, we found intense
Apo D expression in many neurons and glial cells in young
human brainstem nuclei. Immunostaining for Apo D was
usually restricted to the neuronal cytoplasm, with highest
intensity in the perinuclear region. When the signal was strong,
it tended to fill the entire cell, even the neurites, but has been
not observed in the cell nucleus. In general, larger neurons
showed more intense staining for Apo D than smaller neurons.
The number of Apo D-positive glial cells appeared highest at
the periphery compared to the core of these nuclei (Figures
3-5). Finally, motor nuclei exhibited higher Apo D expression
than sensory nuclei (p < 0.006). Again, expression level was
independent of age (Figure 6). The physiological implications of
these observations required further study.
Discussion
In the present study, we found that expression of Apo D in
medulla oblongata and pons is already high in young subjects,
contrary to other areas of the brain previously studied [8,9], and
widely distributed among the different neuronal nuclei in this
region. We examined expression at the cellular level in eleven
such nuclei and found robust expression in neurons, glial cells,
and neuropil even in young brainstem. This is also in contrast
to human cerebral cortex, where little Apo D is localized to
neurons and appears in only a few astrocytes [8,9]. The region-
specific distribution of Apo D expression was first studied in
detail by our group [8] and later reported by others [19,20]. We
previously demonstrated differences in Apo D expression
among neuronal nuclei located in the same brain region [24] or
among neurons of the same area [23]. Moreover, the absence
of Apo D expression appears to enhance neuronal vulnerability
to death [23,24]. Thus, we consider these results significant for
future pathological studies on brainstem in various neurological
diseases. The pattern of Apo D expression in human brain
coincides with other lipocalins that are lipopolysaccharide
(LPS)-inducible [31,32]. The highest level of lipocalin2 (LCN2)
was found in the olfactory bulb, followed by the brainstem,
cerebellum, hypothalamus, and thalamus, with lowest levels in
the striatum, hippocampus, frontal cortex, and somatosensory
cortex of normal mouse brain [33].
In human frontal cortex, expression is higher in white matter
than grey matter due to higher synthesis by oligodendrocytes
[8,9,13,34]. Whether this is also true in brainstem remains to be
determined as the complex distribution of nuclei and fibre
bundles does not allow for easy separation of white and grey
matter for lysate preparation. Nonetheless, we noted the most
intense expression in neurons, particularly larger neurons of
somatomotor nuclei.
Increased expression of Apo D in the CNS has been
associated with aging, neurodegenerative diseases, and
neuropsychiatric disorders. However, the majority of studies on
Apo D have focused on cerebral and cerebellar cortices and
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the hippocampus, areas particularly prone to pathological
changes with age and during the progression of
neurodegenerative diseases. In all these areas, Apo D
expression in young subjects was lower in grey matter than
Figure 4.  Immunohistochemistry for Apo D and amount of Apo D protein in some nuclei along different decades.  A, B)
Dorsal motor nucleus of the vagus (DX). C,D) Nucleus of solitary tractis (NST). E, F) Inferior olivary nucleus (IO). Data presented as
means of relative optical density (ROD). Each point in the graph represents mean density in a x20 field ±standar error of the mean.
Regresion lines and Pearson`s correlation coefficient (r) are also shown. Bar: 40 μm.
doi: 10.1371/journal.pone.0077852.g004
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Figure 5.  Immunohistochemistry for Apo D and amount of Apo D protein in vestibular nuclear complex along different
decades.  A, B) Inferior vestibular nucleus (IVN). C,D) Medial vestibular nucleus (MVN). E, F) Lateral vestibular nucleus (LVN). G,
H) Superior vestibular nucleus (SVN). Data presented as means of relative optical density (ROD). Each point in the graph
represents mean density in a x20 field ±standar error of the mean. Regresion lines and Pearson`s correlation coefficient (r) are also
shown. Bar: 40 μm.
doi: 10.1371/journal.pone.0077852.g005
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white matter, and increased in both tissues with age and
following injury. Apo D expression has also been linked to
cellular senescence and growth arrest in cell culture [13,35],
and expression appears correlated with age in tissues as
diverse as hair follicles and the CNS [14]. Even a previous
study by our group found that Apo D protein and mRNA
increased during normal development and aging in frontal
cortex [9]. Moreover, a similar age-dependent expression was
demonstrated in the frontal cortex of rats and monkeys [36,37].
By contrast, slot blots and densitometric quantification of Apo D
expression revealed that Apo D expression in brainstem is
already high in young to middle-age adults with no history of
Figure 6.  Mean of Apo D protein during aging in each nuclei of medulla oblongata studied.  Nuclei are grouped according
their sensory or motor function. Motor nuclei show higher quantity of Apo D than sensory nuclei. Data presented as means of
relative optical density (ROD). Bars represent mean value of Apo D along all decades.
doi: 10.1371/journal.pone.0077852.g006
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neurodegenerative disease or brain injury. Moreover,
expression was relatively stable during aging, a result
inconsistent with current assumptions that Apo D is an “age-
related” protein.
The underlying molecular mechanisms of CNS aging include
instability of nuclear and mitochondrial genomes,
neuroendocrine dysfunction, oxidative stress, altered calcium
metabolism, and inflammation-mediated neuronal damage [38].
A growing body of evidence points toward oxidative stress
caused by excess reactive oxygen species (ROS) production
as one of the primary determinants of age-related neural
damage [39]. Stressors that cause an extended growth arrest,
such as UV light or hydrogen peroxide, increase Apo D
expression [32]. In fact, the promoter region of the human Apo
D gene contains several stress-activated regulatory elements
like serum, acute phase, and stress response elements (SRE,
APRE, or STRE) [40]. Several studies postulated that Apo D
could have an important function in cellular defence against
age-associated oxidative stress (OS). Indeed, studies on the fly
homologue and the Apo D null mouse [41,42] showed reduced
tolerance to the ROS generator paraquat (PQ) in mutant/null
genotypes, an effect attributed to the control of lipid
peroxidation. Conversely, transgenic animals overexpressing
human Apo D [43,44], cells transfected with the gene for Apo D
[20], or the direct addition of exogenous Apo D [32,45]
protected against oxidants. A recent paper on PQ-treated
cerebellum from transgenic mice supports the hypothesis that
this lipocalin is necessary for a proper CNS response to
physiological and pathological OS. The absence of Apo D
modified the response of genes related to OS management or
myelination, while overexpression of human Apo D in neurons
almost completely abolished the early transcriptional response
to OS [42].
We observed strong Apo D expression in all studied nuclei of
the medulla oblongata and pons from both young and old
subjects, and no statistically significant increase in Apo D
expression with age. Thus, Apo D is not a marker of aging in
the brainstem. Due to these high levels of Apo D, we speculate
that human brainstem is not exposed to damaging OS during
aging, that Apo D expression in this brain region is uniquely
regulated, or that the predominant role for Apo D in this brain
region is distinct from that in other regions. It has long been
known that Apo D is critical for remyelination of rat sciatic
nerve, as evidenced by the > 40-fold increase in expression in
regenerating nerve compared to non-injured control nerve [6].
Elevated expression of Apo D has been found in endoneural
fibroblasts of regenerating crushed nerve in rats [6]. Since Apo
D is released into the extracellular environment, Spreyer et al.
[6] proposed that Apo D participates in intraneural lipid
transport and (or) re-utilization for the biosynthesis of
membranes. In mouse peripheral nerve, Apo D is expressed by
Schwann cells, by satellite cells, and by cells located between
the Schwann cells [34]. We demonstrated that Apo D facilitates
the recovery of locomotor function after injury, promotes myelin
clearance, and regulates the extent of angiogenesis and the
number of macrophages invading the injury site in mouse
crushed sciatic nerve. Moreover, the regeneration and
remyelination of axons were delayed in the absence of Apo D
and stimulated by excess Apo D [7]. In the present study, we
found that motor nuclei have higher levels of Apo D expression
than sensory nuclei. We argue that this may be because motor
nuclei require a greater capacity for myelination and
maintenance of axonal transport.
Finally, Apo D may also regulate neuritogenesis and
synaptogenesis. Co-cultures of adipocytes with peripheral
neurons showed enhanced neurite and synapse formation. It
has reported that apolipoproteins D and E3 exert neurotrophic
and synaptogenic effects in dorsal root ganglion cell cultures
[46]. Considering these results together, we suggest that Apo D
is critical for neural function and homeostasis. The brainstem
exhibits stable expression of Apo D throughout life due to its
critical importance for survival. This brain region contains
centers that regulate several functions vital to survival,
including heartbeat, breathing, blood pressure, digestion,
swallowing, and vomiting. It is also responsible for stimulating
the reticular formation, a region involved in regulation of sleep/
waking patterns and reflexes for maintaining muscle tone,
posture, and gaze.
The effects of aging on the CNS have been studied for more
than a century, but only a few works have focused on effects to
the brainstem. We previously reported that aging is not
associated with neuronal loss in brainstem nuclei [28], only a
shift from larger to smaller neurons and an increase in glial cell
number [27]. Indeed, most studies of the brainstem have found
little neuronal loss and no significant functional impairment. We
previously described a statistically significant neuron decrease
in the VNC during aging, but only in the MVN [28], which could
account for the small deficits in balance observed in older
individuals. One interesting result of the present study was that
the MNV, the only nucleus of the VNC that loses neurons
during aging, had the lowest Apo D expression of all VNC
nuclei. That basal Apo D expression is higher in brainstem than
in grey matter areas that lose neurons during aging and are
generally more sensitive to oxidative stress [8,21,23,24]
strongly suggests that the preservation of brainstem nuclei
during aging is directly related to stable expression of Apo D.
Conclusions
Although the full spectrum of Apo D functions is unclear, the
current study strongly suggests that this molecule is critical for
resistance to age-related neural damage. Neurons that do not
synthesize or import Apo D from surrounding glial cells are
more vulnerable to age- and disease-related death. Diseases
or injuries of the brainstem region are normally incompatible
with life, requiring stable basal expression of Apo D (and
possibly other neuroprotective factors). The results of this study
support the hypothesis that Apo D is a critical neuroprotective
molecule against neurodegenerative disease and the ravages
of age.
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